Zurich Cantonal Bank
SMMT icon

Zurich Cantonal Bank’s Summit Therapeutics SMMT Stock Holding History

Zurich Cantonal Bank’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-424
Closed -$7.42K – 3380
2025
Q4 		$7.42K Hold
424
– – ﹤0.01% 2494
2025
Q3 		$8.76K Sell
424
-204
-32% -$4.95K ﹤0.01% 2506
2025
Q2 		$13.4K Sell
628
-108
-15% -$2.46K ﹤0.01% 2504
2025
Q1 		$14.2K Sell
736
-4,750
-87% -$95.3K ﹤0.01% 2571
2024
Q4 		$97.9K Sell
5,486
-1,126
-17% -$21.8K ﹤0.01% 2442
2024
Q3 		$145K Sell
6,612
-148
-2% -$2.07K ﹤0.01% 2275
2024
Q2 		$52.7K Sell
6,760
-32,233
-83% -$174K ﹤0.01% 2531
2024
Q1 		$161K Sell
38,993
-734
-2% -$2.92K ﹤0.01% 2174
2023
Q4 		$104K Buy
39,727
+14,098
+55% +$29K ﹤0.01% 2436
2023
Q3 		$47.9K Sell
25,629
-653
-2% -$1.25K ﹤0.01% 2608
2023
Q2 		$66K Buy
26,282
+20,568
+360% +$37.5K ﹤0.01% 2520
2023
Q1 		$10K Buy
+5,714
New +$15.6K ﹤0.01% 2794

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Zurich Cantonal Bank's SMMT Position: Q1 2026 in Review

Zurich Cantonal Bank sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 424 shares — an estimated $7.42K sold.

Zurich Cantonal Bank first reported a position in SMMT in Q1 2023 and held it in 12 quarters. The position peaked at $161K in Q1 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Zurich Cantonal Bank reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Zurich Cantonal Bank sold 424 Summit Therapeutics shares in Q1 2026, an estimated $7.42K.
  • Zurich Cantonal Bank first reported a position in Summit Therapeutics in Q1 2023 and held it in 12 quarters.
  • Zurich Cantonal Bank's Summit Therapeutics position peaked at $161K in Q1 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.